In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

From those humble beginnings, it now seems that a new bag-loving predecessor has emerged in 2025: Timothée Chalamet and his love for teeny tiny accessories. Whispery mustache included ...

Learn More ResMed Inc. (ASX: RMD ... The R&D product launch cadence has stepped up with innovative mask and accessories launches over 2HCY24. Our revenue growth estimates for masks are 2.4% ...

How do you know which sleep apnea treatment is right for you? There are a number of ways to treat your symptoms and help you get a restful night’s sleep. Talk with your doctor before you try one.